agilon health (NYSE:AGL) Price Target Cut to $4.00 by Analysts at Evercore ISI

agilon health (NYSE:AGL) had its price target reduced by Evercore ISI from $7.00 to $4.00 in a research note released on Tuesday morning, Benzinga reports. Evercore ISI currently has an in-line rating on the stock.

A number of other equities research analysts have also weighed in on the company. Benchmark restated a buy rating and set a $9.00 price objective on shares of agilon health in a research report on Thursday, August 8th. Deutsche Bank Aktiengesellschaft reduced their price objective on agilon health from $5.00 to $4.00 and set a hold rating on the stock in a research report on Friday, August 9th. Bank of America lowered agilon health from a buy rating to an underperform rating and set a $3.00 price objective on the stock. in a research report on Wednesday, October 2nd. Finally, Royal Bank of Canada restated an outperform rating and set a $8.00 price objective on shares of agilon health in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $8.03.

agilon health Trading Down 3.0 %

Shares of AGL opened at $3.22 on Tuesday. agilon health has a 52-week low of $2.99 and a 52-week high of $20.37. The business’s fifty day moving average is $4.13 and its 200-day moving average is $5.31. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.36 and a current ratio of 1.36. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -4.41 and a beta of 0.54.

agilon health (NYSE:AGL) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.56 billion. agilon health had a negative return on equity of 29.91% and a negative net margin of 5.57%. The company’s revenue for the quarter was up 38.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.04) EPS. Equities analysts anticipate that agilon health will post -0.32 EPS for the current fiscal year.

Insider Activity at agilon health

In related news, CEO Steven Sell bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were bought at an average price of $3.36 per share, for a total transaction of $67,200.00. Following the transaction, the chief executive officer now directly owns 67,590 shares of the company’s stock, valued at approximately $227,102.40. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP lifted its position in shares of agilon health by 2.9% during the 4th quarter. Wellington Management Group LLP now owns 42,510,030 shares of the company’s stock valued at $533,501,000 after acquiring an additional 1,191,253 shares during the period. Vanguard Group Inc. lifted its position in shares of agilon health by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 28,947,798 shares of the company’s stock valued at $176,582,000 after acquiring an additional 371,537 shares during the period. Capital International Investors lifted its position in shares of agilon health by 84.7% during the 1st quarter. Capital International Investors now owns 20,197,932 shares of the company’s stock valued at $123,207,000 after acquiring an additional 9,263,296 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of agilon health by 46.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,139,886 shares of the company’s stock valued at $127,256,000 after acquiring an additional 3,195,087 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of agilon health by 3,338.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock valued at $8,871,000 after acquiring an additional 1,316,990 shares during the period.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.